Comparative Pharmacology
Head-to-head clinical analysis: BROMANATE DM versus BROMFED DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMANATE DM versus BROMFED DM.
BROMANATE DM vs BROMFED-DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist; it also inhibits serotonin reuptake and acts on the cough center. Brompheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors.
Brompheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that acts on the medullary cough center to suppress cough.
2.5 mg orally three times daily (every 8 hours); maximum 10 mg in 24 hours.
1 capsule (brompheniramine maleate 6 mg, dextromethorphan HBr 30 mg) orally every 6 hours, not to exceed 4 capsules per 24 hours.
None Documented
None Documented
Brompheniramine: 24.9 ± 9.3 hours. Dextromethorphan: 3-4 hours for extensive metabolizers (CYP2D6); 24-48 hours for poor metabolizers. Clinical context: Steady state reached in ~5 days for brompheniramine; accumulation in poor metabolizers may require dose adjustment.
Brompheniramine: 24–36 h; pseudoephedrine: 5–8 h; dextromethorphan: 2–4 h (CYP2D6 extensive metabolizers) or up to 24 h (poor metabolizers).
Brompheniramine is primarily excreted via renal elimination (approximately 70-85% as metabolites and unchanged drug). Dextromethorphan and its metabolites are excreted renally (about 60% as unchanged dextromethorphan and dextrorphan glucuronide conjugates). Biliary/fecal excretion accounts for the remainder.
Renal: 60–70% unchanged (brompheniramine); hepatic metabolism and renal excretion of metabolites (dextromethorphan: O-demethylation; pseudoephedrine: 70–90% unchanged in urine). Biliary/fecal: <5%.
Category C
Category C
Cough and Cold Combination
Cough and Cold Combination